Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-04-04
2010-12-14
Nickol, Gary B. (Department: 1647)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S351000, C530S388100, C514S002600, C514S012200, C514S049000, C514S050000, C424S085200, C424S178100, C424S179100, C424S180100, C424S278100, C536S028500, C536S028510
Reexamination Certificate
active
07851599
ABSTRACT:
The invention refers to the use of L19IL2 for treatment of pancreatic cancer. In another embodiment, the invention relates to a combination (i) of a fusion protein, comprising an Interleukin 2 part and an antibody part, specifically recognizing the extra domain B of fibronectin (ED-B-fibronectin), and (ii) gemcitabine.
REFERENCES:
patent: 2004/0013640 (2004-01-01), Zardi et al.
patent: 2007/0189963 (2007-08-01), Neri
patent: WO 9958570 (1999-11-01), None
Rudikoff et al (Proc Natl Acad Sci USA 1982 vol. 79 p. 1979).
Casset et al. (2003) BBRC 307, 198-205.
Chen et al. J. Mol. Bio. (1999) 293, 865-881.
Vajdos et al. (2002) J. Mol. Biol. 320, 415-428.
Wu et al. J. Mol. Biol. (1999) 294, 151-162.
Menard A et al, “ED-B fibronectin as a target for antibody-based cancer treatment”, Expert Opinion on Therapeutic Targets, Ashley Publications, London, GB, vol. 9 No. 3, Jun. 2005, pp. 491-500.
Wagner Karola et al, “Therapeutic efficacy of the targeted cytokine L19-I12 in orthotopic animal models of pancreatic cancer”, Gastroenterology, vol. 128 No. 4 suppl.2, Apr. 2005, p. A78, &, Annual meeting of the American-Gastroenterological-Association/Digestive-Disease-Week; Chicago, IL, USA; May 14-19, 2005.
Menard A et al, “Therapeutic efficacy of the targeted immunocytokine L19-IL2 in orthotopic animal models for pancreatic-and hepatocellular carinoma”, retrieved from http://www.charite.de/fabisch.
Carnemolla Barbara et al, “Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix”, Blood, W.B. Saunders Company, Orlando, FL, US, vol. 99 No. 5, Mar. 1, 2002, pp. 1659-1665.
Kaspar Manuela et al, “Fibronectin as target for tumor therapy”, International Journal of Cancer. Journal International Du Cancer, Mar. 15, 2006, pp. 1331-1339.
Schwarz R E et al, “An orthotopic in vivo model of human pancreatic cancer”, Surgery, Sep. 1999, pp. 562-567.
Toschi L et al, “Role of gemcitabine in cancer therapy”, Future Oncology, London, England, Feb. 2005, vol. 1 No. 1 Feb. 2005, pp. 7-17.
Gramont De A et al, “Investigating the Potential of Bevacizumab in Other Indications: Metastatic Renal Cell, Non-Small Cell Lung, pancreatic and breast cancer”, Oncology, S. Karger AG, Basel, CH, vol. 69 No. suppl 3, Nov. 2005, pp. 46-56.
Halin C et al, “Antibody-based targeting of Angiogenesis”, Critical Reviews in Therapeutic Drug Carrier Systems, vol. 18 No. 3, 2001, pp. 299-339.
J. Yang et al., “Randomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal Cancer”, Journal of Clinical Oncology, vol. 21, No. 16 (Aug. 16, 2003) pp. 3127-3132.
U. Keilholz et al., “Dacarbazine, Cisplatin, and Interferon-Alfa-2b With or Without Interleukin-2 in Metastatic Melanoma : A Randomized Phase III Trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group”, Journal of Clinical Oncology, vol. 23, No. 27 (Sep. 20, 2005) pp. 6747-6755.
D. Moosmayer et al., “Bispecific Antibody Pretargeting of Tumor Neovasculature for Improved Systemic Radiotherapy of Solid Tumors”, Clin. Cancer Res., vol. 12, No. 18 (Sep. 15, 2006) pp. 5587-5595.
J. Yang et al., “An Ongoing Prospective Randomized Comparison of Interleukin-2 Regimens for the Treatment of Metastatic Renal Cell Cancer”, Cancer J. Sci. Am., vol. 3 (1997) pp. S79-S84.
A. Hauschild et al., “Dacarbazine and Interferon α With or Without Interleukin 2 in Metastatic Melanoma : A Randomized Phase III Multicentre Trial of the Dermatologic Cooperative Oncology Group (DeCOG)”, British Journal of Cancer, vol. 84, No. 8 (2001) pp. 1036-1042.
M. Atkins et al., “High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993”, Journal of Clinical Oncology, vol. 17, No. 7 Jul. 1999 pp. 2105-2116.
J. Plate et al., “Effect of Gemcitabine on Immune Cells in Subjects with Adenocarcinoma of the Pancreas”, Cancer Immunol. Immunother., vol. 54 (2005) pp. 915-925.
A. Nowak et al., “Gemcitabine Exerts a Selective Effect on the Humoral Immune Response : Implications for Combination Chemo-Immunotherapy”, Cancer Research, vol. 62 Apr. 15, 2002 pp. 2353-2358.
A. Nowak et al., “Synergy between Chemotherapy and Immunotherapy in the Treatment of Established Murine Solid Tumors”, Cancer Research, vol. 63 (Aug. 1, 2003) pp. 4490-4496.
Nowak et al. “Gemcitabine Exerts a Selective Effect on the Humoral Immune Response: Implications for Combination Chemo-immunotherapy.”Cancer Research, 62, 2353-2358, Apr. 15, 2002.
Gramont et al. “Investigating the Potential of Bevacizumab in Other Indications: Metastatic Renal Cell, Non-Small Cell Lung, Pancreatic and Breast Cancer.”Oncology69 (suppl 3):46-56, 2005.
Toschi et al, “Role of gemcitabine in cancer therapy.”Future Oncology, vol. 1, No. 1, pp. 7-17, 2005.
Daikeler et al. “The influence of gemcitabine on the CD4/CD8 ratio in patients with solid tumours.”Oncology Reports, 4: 561-564, 1997.
Bonnema et al. “Cytokine-enhanced NK cell-mediated cytotoxicity. Positive modulatory effects of IL-2 and IL-12 on stimulus-dependent granule exocytosis.”The Journal of Immunology, vol. 152, Issue 5 2098-2104, 1994.
Wang et al. “IL-2 induces STAT4 activation in primary NK cells and NK cell lines, but not in T cells.”The Journal of Immunology, vol. 1; 162(1):299-304, 1999.
Menrad Andreas
Menssen Hans Dietrich
Wagner Karola
Gamett Daniel C
Millen White Zelano & Branigan P.C.
Nickol Gary B.
Philogen S.p.A.
LandOfFree
Combination of an anti-ED—B fibronectin domain... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination of an anti-ED—B fibronectin domain..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination of an anti-ED—B fibronectin domain... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4199605